We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Kendle, a leading, global full-service clinical research organization, today
announced the opening of an office in New Delhi, India, further expanding its
access to large patient populations in the Asia/Pacific region.
Oxxon Therapeutics has licensed exclusive worldwide rights to Xenova Group's
DISC-HSV and DISC-GM-CSF vector platforms for use in developing products for
certain major cancers and chronic infectious diseases.
Bradley Pharmaceuticals has reached agreement with DPT Laboratories and its
affiliate DPT Lakewood to continue manufacturing Zonalon, a topical dermatological
preparation, and other products.
C.R. Bard, a New Jersey company, said it is buying
the assets of Genyx Medical, related to its implantable treatment for incontinence,
for $60 million.
New research showing that Genentech's colorectal cancer drug Avastin may pose
an increased risk of arterial thromboembolic events in patients undergoing chemotherapy
has prompted the firm to alter the drug's labeling.
GlaxoSmithKline (GSK) has agreed to sell the majority of its international co-promotion
rights to erectile dysfunction drug Levitra to Bayer for approximately $260
million.
In a recent court decision that indicates authorized generics
may be here to stay, Judge Reggie Walton of the U.S. District Court for the
District of Columbia denied Teva Pharmaceutical's motion for summary judgment
in a lawsuit the generic drugmaker filed against the FDA.
Patent settlements between brand and generic drugmakers have increased in recent
years, and the agreements are being completed without payments from the brand
to the generic in exchange for the generic's commitment not to market the product,
according to a new federal study.
ISTA Pharmaceuticals has announced plans to offer 4,500,000 shares of its common
stock in an underwritten public offering pursuant to its existing and effective
shelf registration statement.
Corixa, a developer of immunotherapeutics, has signed a license agreement with
Genentech in which Corixa will grant Genentech exclusive worldwide rights to
a novel target for the possible development of humanized antibody-based therapeutics.